More Related Content Similar to 2.1 Le Blanc (20) More from Kate Jones (20) 2.1 Le Blanc1. ISBM, Manchester UK, 9th â 11th September 2013Â
HOW CONFIDENT ARE WE?
Alain LeBlanc
Special projectsâ manager,
support services and external quality assessment
Centre de toxicologie du QuĂŠbec (CTQ) Â
INSPQ, QuÊbec, Canada
Pierre Dumas
Research & Development division
3. QUEBEC MINISTRY OF HEALTH AND WEALTHFARE (MSSS)
INSTITUT NATIONAL DE SANTĂ PUBLIQUE DU QUĂBEC (INSPQ)
ENVIRONMENTAL HEALTH AND TOXICOLOGY DEPT. (DSET)
CENTREÂ DEÂ TOXICOLOGIEÂ DUÂ QUĂBECÂ (CTQ)
Claude Thellen
QUALITYÂ MANAGEMENT
Sergine Lapointe
TOXICOLOGY
LABORATORYÂ BRANCH
Normand Fleury
SPECIAL PROJECTS, SUPPORTÂ
SERVICES and EQAS SECTOR
Alain LeBlanc
RESEARCH
Pierre Ayotte
METHODÂ
DEVELOPMENT
Patrick BÊlanger
CLINICAL
ORGANICS
Michel Lefebvre
Eric Gaudreau
METALS
CiprianâMihai
Cirtiu
PROJECTÂ Â
MANAGEMENT
and  SUPPORT
SERVICES
EXTERNALÂ
QUALITYÂ
ASSESSMENTÂ
SCHEMES
7. Analytical standardsÂ
â˘
â˘
Availability of conjugated analytes
Accuracy (certificates, multiple sources)
Impact on biomonitoring data (cycle to cycle)
Availability of appropriate internal standards
13C labeled and unlabeled analogs are usually not available at the same time
⢠Custom synthesis (TRC, CANSYN, CHIRON, CIL, etc)
High cost, time to delivery, lotâtoâlot, purity (UV, NMR, IR and MS spectra)
â˘
â˘
Analytical methods
â˘
â˘
â˘
â˘
Classical versus experimental protocols
Sensitivity (LODs) and specificity
Reportable limits (no international consensus; study comparisons)
Laboratory contamination (ex: BPA, Triclosan, Parabens, BDEs, âŚ)
10. Sample Temperature Tracking Chart
ÂŤ Freeze/thaw Âť
30
Temperature °C
20
10
0
-10
-20
-30
Sample handling: Chronological events
(worst case scenario)
16. Supplier
MMP
MEP
MiBP
MnBP MCHP
MBzP
MEHP MEHHP MEOHP MECPP
MOP
MCPP
MNP
CILâ2006
â25%
â2%
â
â47%
â1%
â63%
â29%
â11%
â7%
â
12%
â22%
â39%
CILâ2009
â9%
Certified
solutions CILâ2010
â11%
â5%
â13%
â12%
â76%
â14%
â21%
4%
3%
2%
â70%
â16%
â3%
â9%
0%
â11%
â7%
3%
â11%
â19%
â9%
â2%
3%
â78%
â10%
â
â
â3%
â
â
â
â
â
â
â
â
â
â
Accustandard
â26%
â31%
â
â19%
â
â4%
â27%
â
â
â
â
â
â
Accustandard
8%
â7%
â
â5%
â
â2%
â27%
â
â
â
â
â
â
Aldrich
9%
â
â
â6%
â
â5%
â
â
â
â
â
â
â
Chiron
Chiron
â
â21%
â
0%
â
â
â
â
â
â
â
â
â
Neat
standards Dr Ehrenstorfer
13%
â
â
â2%
â
â
â29%
â
â
â
â
â
â
CanSyn
9%
â5%
4%
â1%
â6%
â1%
â8%
â6%
â4%
â1%
10%
â7%
â3%
CIL
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
TRC
7%
â3%
4%
â6%
â10%
â2%
â11%
9%
9%
â70%
12%
â2%
â6%
Langlois E., LeBlanc A., Simard Y., Thellen C. Accuracy investigation of phthalate metabolite standards
Journal of Analytical Toxicology, 2012 ; 36 :270-279
29. 40
BPA
35
y = 0.9149x - 0.0207
R² = 0.9946
BPA total Âľg/L (GC)
30
25
20
15
10
5
0
0
5
10
15
20
25
30
35
40
BPA free + BPA-glucuronide + BPA-sulfate + BPA-disulfate in Âľg BPA eq./L (LC)
LCâMS/MSÂ VSÂ GCâMS/MS
30. 900
Triclosan
800
y = 1.0229x + 0.1818
R² = 0.9954
700
TCS total Âľg/L (GC)
600
500
400
300
200
100
0
0
100
200
300
400
500
600
700
800
900
TCS free + TCS-glucuronide + TCS-sulfate Âľg in TCS eq./L (LC)
LCâMS/MSÂ VSÂ GCâMS/MS
33. EQAS
Blood lead (17)
AAFP CAP DigitalPt GâEQUAS LAMP NEQAS NYSDH OELM PCI Penn QMEQAS RCPA SEKK SKZL TEQAS WIVâISP WSLH
Urine BPA (1)
GâEQUAS
Urine Triclosan (0)
Urine Triclocarban (0)
RM
Blood lead (6)
IAEA IRMM NIST RECIPE SERONORM UTAK
Urine BPA (1)
RECIPE [NIST]
Urine Triclosan (0)
[NIST]
Urine Triclocarban (0)
35. ⢠3 continuing programs in blood, urine, serum and hair
Metals: PCI, QMEQAS      POPs: AMAP
⢠Material from human origin; unexposed volunteers
⢠2 developing programs: MDA, Organic compounds in urine
⢠Voluntary participation
⢠Funded by the participants
⢠Reference material virtual store
37. ⢠Laboratories involved in HBM face challenges at all levels of operation
⢠Competence of staff must be developped and maintained
⢠Method validation must be brought to a higher level
(stability, matrix effect, comparability of standards, âŚ)
⢠Importance of External quality assessment schemes and reference
materials is obvious
adapted QA strategy (work to do)
⢠A laboratory facility with a scientific and administratrive infrastructure is
mandatory
⢠The term ÂŤ new contaminant  alone shouldnât set the rationale forÂ
biomonitoring
⢠A reference laboratory must have the capabilities and experience toÂ
tackle these recurring issues (not necessarily compatible with every
laboratory structure)